A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6284-6294

  Molife, L Rhoda ^a,e   Dean, Emma Jane ^b   Blanco Codesido, Montserrat ^a   Krebs, Matthew G ^b   Brunetto, Andre T ^a   Greystoke, Alastair Peter ^b   Daniele, Gennaro ^a   Lee, Lucy ^c   Kuznetsov, Galina ^c   Myint, Khin Than ^c   Wood, Karen ^d   De Heras, Begõna Las ^d   Ranson, Malcolm Richard ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c EISAI INC   (United States)

^d EISAI CO LTD   (Japan)

^e Drug Development Unit Sycamore House Royal Marsden   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPHRIN RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; GOLVATINIB; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2; AMINOPYRIDINE DERIVATIVE; BIOLOGICAL MARKER; N-(2-FLUORO-4-((2-(4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL)CARBONYLAMINOPYRIDIN-4-YL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT TUMOR; BLADDER TUMOR; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COLORECTAL TUMOR; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; ESOPHAGUS TUMOR; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; KIDNEY TUMOR; LUNG TUMOR; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PAROTID GLAND TUMOR; PERIPHERAL NERVE TUMOR; PERITONEUM TUMOR; PHASE 1 CLINICAL TRIAL; SOLID TUMOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; BLOOD; CANCER STAGING; CLINICAL TRIAL; DRUG MONITORING; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AMINOPYRIDINES; BIOMARKERS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84919684779     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0409     Document Type: Article

References (50)

1. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316-25.
2. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008;100:1-33.
3. WangMH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 1994;266:117-9.
4. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
5. Trusolino L, Bertotti A, Comoglio PM. MET signaling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
6. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplifi cation leads to gefi tinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316: 1039-43.
7. Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012;7:459-67.
8. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Oliverio M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119:629-41.
9. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993;90:1937-41.
10. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 2003;100:12718-23.
11. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15:5020-25.
12. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013;39:793-801.
13. Sierra JR, Tsao MS. C-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011;3(1 Suppl): S21-35.
14. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
15. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic signi ficance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-902.
16. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. C-Met gene ampli fi cation is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008;265: 258-69.
17. Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. HighMETgene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010;5:305-13.
18. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
19. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47: 1025-37.
20. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009;69:3021-31.
21. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000;19:4947-53.
22. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006;66:352-61.
23. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in nonsmall cell lung cancer. Cancer Res 2005;65:1479-88.
24. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-Met mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-81.
25. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol 1997; 9:608-15.
26. Pasquale EB. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 2004;7:417-18
27. Carmeliet P, Jain R. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
28. Lisle JE, Mertens-Walker I, Rutkowski R, Herington AC, Stephenson SA. Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer. Biochim Biophys Acta 2013;1835:243-57.
29. Hafner C, Schmitz G, Meyer S, Battaille F, Hau P, Langmann T, et al. Differential gene expression of Eph receptors and Ephrins in benign human tissues and cancers. Clin Chem 2004;50:490-9.
30. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small lung cancer. Clin Cancer Res 2009;15:4423-30.
31. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, et al. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther 2010;10: 1306-14.
32. Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 2008;3: e2994.
33. Oki M, Yamamoto H, Taniguchi H, Adachi Y, Imai K, Shinomura Y. Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J Gastroenterol 2008;14:5650-6.
34. Wang LF, Fokas E, Juricko J, You A, Rose F, Pagenstecher A, et al. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer 2008;8:79.
35. th Annual Meeting; 2013 Apr 6-10;Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr 1619.
36. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, et al. E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010;101:210-5.
37. Nakazawa Y, Kawano S, Matsui J, Funahashi Y, Tohyama O, Muto H, et al.Maximising the efficacy of anti-angiogenesis cancer therapy: Multi-targeting strategy by tyrosine kinase inhibitors [abstract]. In: Proceedings of the Annual Meeting of the American Association of Cancer Research; 2014 Apr 5-9; San Diego, CL. Philadelphia (PA): AACR; 2014. Abstract nr 2947.
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
39. Lager DJ, Huston BJ, Timmerman TG, Bonsib SM. Papillary renal tumors: morphologic, cytochemical, and genotypic features. Cancer 1995;76:669-73.
40. Doi T, Yoshino T, Fuse N, Bando H, Tahara M, Ohki M, et al.Phase 1 dose- finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administrated orally BID to patients with advanced solid tumors. J Clin Oncol 2012;30 (suppl; abstr 3079).
41. Mistry B, Nishioka Y, Fan J, Verbel D. Assessment of effect of low- and high-fat diet on E7050 pharmacokinetics and characterization of E7050 pharmacokinetics after 100 mg, 200 mg, and 400 mg single oral doses in healthy subjects. Mol Cancer Ther 2011;10. Abstract no. A193.
42. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14:453-9.
43. Nakagawa T, Matsushima T, Kawano S, Nakazawa Y, Kato Y, Adachi Y, et al. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-inducted resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci 2014;105: 723-30.
44. Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010;16:3507-16.
45. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/ VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31:181-6.
46. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small cell lung cancer. J Clin Oncol 2011;29:3307-15
47. Wakelee HA, Gettinger SN, Engelman JA, Janne PA, West HJ, Subramaniam DS, et al. A phase IB/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small lung cancer (NSCLC). J Clin Oncol 28:15s, 2010 (suppl;abstr 3017).
48. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final effi cacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol29:15s, 2011 (suppl; abstr 7505).
49. Shah MA, Wainberg ZA, Catenacci VT, Hochser HS, Ford J, Kunz P, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR Inhibitor, in patients with metastatic gastric cancer. PLoS ONE 2013;8:e54014.
50. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013;39: 793-801.